Q3 25 EPS
$-0.05
BEAT +51.22%
Est. $-0.10
Q3 25 Revenue
$12.9M
BEAT +7.30%
Est. $12.0M
vs S&P Since Q3 25
+5.7%
BEATING MARKET
APYX +20.9% vs S&P +15.2%
Market Reaction
Did APYX Beat Earnings? Q3 2025 Results
Apyx Medical delivered a notably strong third quarter, posting a loss of just $0.05 per share against a consensus estimate of $0.10, a 51.22% beat, while revenue climbed 12.1% year over year to $12.88 million, clearing the $12.00 million estimate by … Read more Apyx Medical delivered a notably strong third quarter, posting a loss of just $0.05 per share against a consensus estimate of $0.10, a 51.22% beat, while revenue climbed 12.1% year over year to $12.88 million, clearing the $12.00 million estimate by 7.30%. The primary engine behind the outperformance was the full commercial launch of its AYON Body Contouring System, which fueled a 19% surge in Surgical Aesthetics revenue and a domestic sales spike of over 30%, pushing gross margin to 64.4% from 60.5% a year earlier. Cost discipline added to the momentum, with operating expenses falling $1.50 million to $9.13 million, helping narrow the net loss sharply to $1.98 million from $4.70 million in the prior-year period. Analysts who follow medical device earnings beats this season have noted how margin expansion can accelerate loss reduction, and Apyx fits that pattern. The company raised its full-year 2025 revenue guidance to $50.50 million–$52.50 million, with Surgical Aesthetics guidance lifted to $43.00 million–$45.00 million as the AYON commercial ramp continues.
Key Takeaways
- • AYON commercial launch drove Surgical Aesthetics revenue growth of 19% YoY
- • Domestic Surgical Aesthetics sales increased over 30% from prior year period
- • Increased volume of single-use handpieces in both domestic and international markets
- • Favorable segment mix with Surgical Aesthetics comprising a higher percentage of total sales improved gross margin to 64.4%
- • Operating expenses decreased $1.5 million year-over-year through broad-based cost reductions
APYX YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
APYX Revenue by Segment
With YoY comparisons, source: SEC Filings
APYX Revenue by Geography
With YoY comparisons, source: SEC Filings
“In September, we successfully transitioned the commercialization program for AYON from an effective soft launch targeting key regions to a full U.S. program. Initial feedback from leading board-certified plastic and cosmetic surgeons continues to be overwhelmingly positive, with several of them contributing at workshops and clinical symposia that drove strong engagement and resulted in pre-orders for AYON. While we are still in the early stages of ramping up the broader commercial program, I am excited to announce that we reported a 19% increase in Surgical Aesthetics revenue for the third quarter of 2025,”
— Charlie Goodwin, Q3 2025 Earnings Press Release
APYX Earnings Trends
APYX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
APYX EPS Trend
Earnings per share: estimate vs actual
APYX Revenue Trend
Quarterly revenue: estimate vs actual
APYX Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.08 | $-0.07 | +14.63% | $13.9M | +5.38% |
| Q1 26 BEAT | $-0.10 | $-0.05 | +50.00% | $12.5M | +9.13% |
| Q4 25 BEAT FY | $-0.06 | $-0.03 | +46.43% | $19.2M | +0.21% |
| FY Full Year | $-0.30 | $-0.27 | +11.18% | $52.8M | +1.19% |
| Q3 25 BEAT | $-0.10 | $-0.05 | +51.22% | $12.9M | +7.30% |
| Q2 25 BEAT | $-0.09 | $-0.09 | +0.00% | $11.4M | -2.79% |
| Q1 25 BEAT | $-0.12 | $-0.10 | +13.04% | $9.4M | +1.04% |